Liver flukes are small flatworms that live for years in the bile ducts. They infect tens of millions of people, mostly in East and Southeast Asia, Eastern Europe and parts of South America. This article covers four things. It explains how praziquantel treats the two fish-borne flukes, Clonorchis sinensis and Opisthorchis species, and how well it works. It sets out the strong evidence that long-standing infection with these flukes causes cholangiocarcinoma, a cancer of the bile ducts. It explains why the sheep liver fluke, Fasciola, does not respond to praziquantel and needs a different drug, triclabendazole. Finally, it covers what patients and families can reasonably do to protect themselves.
The fish-borne liver flukes and how people catch them
Clonorchis sinensis, the Chinese liver fluke, is found mainly in southern China, Korea, northern Vietnam and the Russian Far East. Opisthorchis viverrini is concentrated in the Mekong basin, especially northeast Thailand, Laos, Cambodia and southern Vietnam. A close relative, Opisthorchis felineus, occurs in Siberia and parts of Eastern Europe. Commonly cited estimates put Clonorchis infections at around 15 million, most of them in China, and O. viverrini infections at roughly 10 million.
The life cycle runs through freshwater snails and then freshwater fish, usually carp-family species. People are infected by eating fish that is raw, undercooked, lightly fermented, pickled or salted. Traditional dishes such as raw fish salads carry the larval cysts straight to the small intestine. From there, the young flukes move up into the bile ducts. They can survive there for 20 years or more.
Most infections cause few or no symptoms, which is why they persist unnoticed for decades. Heavier or long-standing infections can cause:
- discomfort in the upper right abdomen, indigestion and fatigue
- inflammation and thickening of the bile duct walls
- gallstones, bile duct stones and recurrent cholangitis (infection of the bile ducts)
- in some people, cholangiocarcinoma after many years
The usual diagnosis is finding eggs in stool under a microscope. The eggs of Clonorchis and Opisthorchis look almost identical, so a patient's travel and dietary history matters a great deal. Light infections are easily missed, and a single negative stool test does not rule infection out.
How praziquantel works against these flukes, and how well
Praziquantel is a synthetic compound. It was developed in the 1970s through a collaboration between German pharmaceutical researchers, and it transformed the treatment of flatworm diseases. Within minutes of exposure, susceptible flukes undergo a rush of calcium into their tissues. Their muscles contract into spastic paralysis, and their outer surface (the tegument) blisters and breaks down. This exposes the worm to the host's immune system.
For decades the precise target was unknown. Work from Jonathan Marchant's laboratory at the Medical College of Wisconsin, published in the Journal of Biological Chemistry in 2019, identified it in schistosomes. The target is a calcium-permeable ion channel of the TRPM family, since named TRPMPZQ. This is laboratory evidence from cell-based and parasite studies, but it has been replicated and is now widely accepted.
In the United States, praziquantel is FDA-approved for schistosomiasis and for infections with Clonorchis sinensis and Opisthorchis viverrini. The standard regimen for individual patients is 25 mg/kg taken three times in one day. In mass-treatment programmes, the World Health Organization recommends a single 40 mg/kg dose because it is simpler to deliver.
The evidence on effectiveness is solid but more modest than often assumed. Older studies reported cure rates near or above 90%. A randomised phase 2 trial in Laos, led by the Swiss Tropical and Public Health Institute and published in The Lancet Infectious Diseases in 2011, gave a more sobering picture. In that trial, the three-dose regimen cleared O. viverrini eggs from stool in only about half of patients. Egg counts nonetheless fell by well over 95%. In practice, praziquantel almost always cuts the worm burden dramatically, but some people need re-treatment. The related drug tribendimidine has shown promise in trials and is approved in China. It is not approved for liver flukes in the United States or Europe.
Praziquantel is generally well tolerated. Common side effects are short-lived:
- abdominal discomfort, nausea, headache and dizziness
- drowsiness. Product labelling advises against driving or operating machinery on the day of treatment and the following day.
Some interactions and precautions matter:
- Strong enzyme-inducing drugs such as rifampicin can lower praziquantel levels so far that treatment fails. Grapefruit juice raises them.
- It is contraindicated in cysticercosis of the eye.
- Breastfeeding mothers are advised to pause nursing for about three days after treatment.
Pregnancy deserves particular care. A randomised, placebo-controlled trial in the Philippines, published in Clinical Infectious Diseases in 2016, treated women for schistosomiasis at 12 to 16 weeks of gestation. It found no significant safety concerns for mother or baby. The WHO supports treatment in pregnancy where infection is significant. Two lives are at stake, so whether to treat during pregnancy or wait until after delivery is a decision for the mother and her physician to weigh together.
From chronic infection to bile duct cancer: what the evidence shows
The link between these flukes and cholangiocarcinoma is among the best-established examples of an infection causing cancer. The International Agency for Research on Cancer classifies both O. viverrini and C. sinensis as Group 1 carcinogens, its highest level of certainty. O. viverrini received this classification in 1994. C. sinensis was upgraded in 2009. O. felineus remains unclassifiable for now, largely because data are limited.
The evidence rests on several independent lines that point the same way:
- Geography. Khon Kaen province in northeast Thailand, where O. viverrini is endemic, has recorded some of the highest cholangiocarcinoma rates anywhere in the world.
- Human studies. Case-control and cohort studies in Thailand and Korea consistently show higher cancer risk in people with evidence of infection.
- Animal experiments. In hamsters, fluke infection combined with dietary nitrosamines reliably produces bile duct tumours. Neither factor alone is as potent.
Researchers such as Banchob Sripa at Khon Kaen University and collaborators abroad have described several overlapping mechanisms. The flukes physically damage the bile duct lining as they feed. They secrete proteins, including a growth-factor-like molecule called granulin, that drive cell proliferation and wound-healing responses. Laboratory studies have shown this effect, and gene-editing experiments in the flukes support it. Years of inflammation then generate oxidative DNA damage. Nitrosamines from fermented fish products likely add to the risk. The cancer typically appears after decades of infection, is often found late and carries a poor prognosis.
Does treatment prevent the cancer?
Here honesty requires care. Clearing the infection removes the ongoing source of injury, and it is plainly worth doing. But no randomised trial has shown that praziquantel treatment lowers cholangiocarcinoma rates. Such a trial would be very difficult to run. Damage already done to the bile ducts may not fully reverse.
Some observational studies from northeast Thailand found higher cancer rates among people treated repeatedly with praziquantel. Most researchers interpret this as a marker of repeated heavy infection, not harm from the drug. Better-designed studies are needed to settle the question.
The most encouraging results come from combining treatment with prevention. The Lawa Project around Lawa Lake in Khon Kaen paired praziquantel with community education, school curricula and attention to sanitation and the snail-fish cycle. It reported substantial falls in infection in participating villages. Thailand's Cholangiocarcinoma Screening and Care Program, launched in 2013, uses ultrasound to find cancers earlier in at-risk adults. The lesson is that a pill alone does not protect a family when the same meal reinfects them the following month.
Why fascioliasis does not respond and needs triclabendazole
Fasciola hepatica and Fasciola gigantica are larger flukes, chiefly parasites of sheep and cattle. People usually become infected by eating watercress or other water plants carrying larval cysts, or by drinking contaminated water. Human disease is particularly common in the Bolivian Altiplano, Peru, Egypt and Iran, with sporadic cases elsewhere.
Fasciola follows a different route through the body. Young flukes burrow through the intestinal wall and cross the abdominal cavity. They then tunnel through the liver itself for weeks before settling in the bile ducts. This acute phase can cause fever, liver pain, weight loss and very high eosinophil counts, a type of white blood cell. Eggs do not appear in stool until roughly three to four months after infection, so blood antibody tests are often used early on. Fasciola is not classified as a cause of cancer.
Praziquantel, so reliable against its fish-borne cousins, consistently fails against Fasciola in clinical use. The likely reason emerged from the same line of research that identified praziquantel's target. Laboratory work from Marchant's group, published in Science Translational Medicine in 2021, examined Fasciola's version of the TRPMPZQ channel. It found a difference at a key site in the drug-binding pocket that makes the channel insensitive to praziquantel. This is a cell-based finding, but it offers a coherent molecular explanation for decades of clinical observation.
Triclabendazole, a benzimidazole drug, is the treatment of choice. Unlike praziquantel, it kills both the migrating juvenile flukes and the adults. It is usually given as 10 mg/kg, sometimes as two doses about 12 hours apart, with food to improve absorption. The FDA approved it for fascioliasis in 2019 for patients aged six and older. The WHO lists it as an essential medicine.
Resistance to triclabendazole is widespread in livestock flukes. Human treatment failures have been reported in countries including the Netherlands, Chile and Peru. Nitazoxanide has been used as an alternative, with inconsistent results. It is not approved for this purpose.
Practical stewardship for patients and families
These infections are largely preventable, and prevention starts in the household kitchen. Thorough cooking reliably kills fluke larvae in fish and on water plants. Salting, pickling, smoking, light fermenting and marinating in lime juice do not. Washing watercress does not reliably remove Fasciola cysts, so cooking it is the safer course.
Anyone who grew up in an endemic region, or who has eaten raw freshwater fish or wild watercress while travelling, should tell their doctor. Infection can sit silently for decades, and a simple stool or blood test can settle the question. The body is remarkably made, and the liver has a striking ability to heal once a source of injury is removed. Diagnosis and treatment give it that chance. Decisions about testing, treatment and follow-up belong with the patient and their own physician, made with a clear understanding of the benefits, limits and alternatives.
Key takeaway: Praziquantel is an effective, well-tolerated treatment for the fish-borne liver flukes that cause bile duct cancer, but it does not work against Fasciola, which requires triclabendazole, and for every liver fluke, cooking food thoroughly remains the surest protection.
